

Blosozumab

Cat. No.:	HY-P99186
CAS No.:	1132758-87-2
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Blosozumab (LY2541546) is an anti-Human sclerostin (SOST) antibody inhibitor. Blosozumab stimulates bone formation and reduces bone resorption. Blosozumab can be used in the research of Osteoporosis ^{[1][2]} .	
IC₅₀ & Target	sclerostin (SOST) ^[1]	
In Vivo	Blosozumab (1-100 mg/kg, i.v.) shows effects of hyperostosis in rats ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Sprague-Dawley rats ^[2]
	Dosage:	1, 10, and 100 mg/kg
	Administration:	Intravenous injection (i.v.), once every 3 days (5-week study) or once weekly (6-month study)
	Result:	Observed the bone anabolic effects. Showed significant bleeding and morbidity at 100 mg/kg. Decreases in the numbers of platelets. Increased number of bone marrow megakaryocytes at 100 mg/kg.

REFERENCES

[1]. Robert R Recker, et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. *J Bone Miner Res.* 2015 Feb;30(2):216-24.

[2]. Daniel G Rudmann, et al. Rat-specific decreases in platelet count caused by a humanized monoclonal antibody against sclerostin. *Toxicol Sci.* 2012 Feb;125(2):586-94.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA